ArticlebioRxiv : the preprint server for biology2026
Evolution of oncogene amplification across 86,000 cancer cell genomes.
Jake June-Koo Lee, Sohrab Salehi, Matthew A Myers, Marc J Williams, Melissa A Yao, Duaa H Al-Rawi, Jin Lee, Eric G Sun, Kerstin Thol, Seongmin Choi and 22 more
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
32 authors.
Jake June-Koo LeeHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1348-4094 Sohrab SalehiHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Matthew A MyersHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9337-5180 Marc J WilliamsHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5524-4174 Melissa A YaoCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-2274-6925 Duaa H Al-RawiHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9218-6513 Jin LeeDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eric G SunCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9109-1969 Kerstin TholHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4624-118X Seongmin ChoiHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9722-1800 Eliyahu HavasovHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Asher Preska SteinbergHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8694-7224 Michelle WuHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nicole RuskHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2663-6288 Caitlin TimmonsHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4118-4902 Cheryl Zi Jin PhuaHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5416-0200 Stephen MartisHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1735-2347 Neeman MohibullahIntegrated Genomics Operation, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Esther RedinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Álvaro Quintanal-VillalongaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7234-3446 Samuel AparicioDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.ORCID 0000-0002-0487-9599 Natasha RekhtmanDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5801-3144 Viviane TabarCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-1284-1670 Helena A YuDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kenny Kwok Hei YuCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-2394-4990 Andrea VenturaCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4320-9907 Andrew McPhersonHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-5654-5101 Sohrab P ShahHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6402-523X Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MExploiting markers of genomic instability in high-risk pre-invasive ovarian cancerR01CA281928 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sohrab P Shah · 2023 to 2026
$2.9MInvestigating the roles of oncogenic extrachromosomal circular DNAs in cancerR01CA282913 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Ventura · 2023 to 2026
$2.2MGenome instability associated with oncogene amplification and its therapeutic strategyK08CA301011 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Jake June-Koo Lee · 2025 to 2026
$584kCausal determinants of drug resistance and metastasis in cancer with multimodal single cell dataK99CA277562 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SALEHI, SOHRAB · 2023 to 2024
$232kNCI NIH HHS K08 CA301011NCI NIH HHS K99 CA277562NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA281928NCI NIH HHS R01 CA282913
6 · The paper itselfAbstract
High-level copy-number (CN) amplification (HLAMP) is a major mechanism of oncogene activation in human cancer. Despite progress in therapeutically targeting amplified oncogenes, the processes underlying amplicon evolution remain incompletely understood, leaving critical knowledge gaps in their etiology and mechanisms of therapeutic response. To address this, we analyzed the evolutionary trajectories of HLAMPs using single-cell whole-genome sequencing data from 86,239 cancer cells across 93 patients and 9 experimental systems. We found that cell-to-cell CN variability provides a quantifiable readout of HLAMP mechanism, clearly distinguishing extrachromosomal circular DNA (ecDNA) from intrachromosomal amplification (ICamp) through characteristic CN distributions that reflect distinct modes of segregation and correspond to clonal architecture. Notably, ICamp events frequently showed multiple amplitude peaks specific to subclones, indicating punctuated shifts in oncogene dosage through numeric or structural modulatory mechanisms with transcriptional impact. In contrast, ecDNAs exhibited broad, continuous CN distribution with extreme high-copy outliers, consistent with asymmetric segregation. The CN and structural diversity of ecDNA regions enabled systematic deconvolution of ecDNA subspecies and estimation of their per-cell abundance, revealing the history of ecDNA-mediated oncogenesis at single-nucleotide resolution. We observed ecDNA diversification through internal rearrangements across cases and, notably, convergent evolution in glioblastoma cases marked by multiple, recurrent acquisition of
Identifiers
PMID41727087
PMCPMC12918801
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390